Opportunity Information: Apply for RFA CA 09 022
Apply for RFA CA 09 022
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Community Clinical Oncology Program (U10)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.399 Cancer Control.
- This funding opportunity was created on May 4, 2009 and posted on May 4, 2009.
- Applicants must submit their applications by Jul 8, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $21,200,000.00 to eligible and selected applicants.
- Eligible applicants include: Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Community Clinical Oncology Program (CCOP) (U10) funding opportunity (RFA-CA-09-022) was a National Cancer Institute (NCI), National Institutes of Health (NIH) initiative designed to strengthen and expand a nationwide community-based cancer clinical trials network. The CCOP Network, originally established in 1983, was built around the idea that high-quality, state-of-the-art cancer clinical research should not be limited to major academic medical centers. Instead, it should be actively carried out in the community settings where most patients actually receive care, with community oncologists playing a central role in enrolling participants and delivering protocol-based interventions.
At its core, the program aimed to advance cancer prevention, cancer control, and cancer treatment research by increasing patient and participant enrollment (accrual) into NCI-approved clinical trials. By improving accrual in community sites, the program sought to speed up the development and evaluation of interventions that prevent cancer, treat cancer, and manage cancer-related symptoms. A second major goal was improving the overall quality of cancer care in the community by promoting the adoption of evidence generated by clinical trials, helping new standards of care move more quickly from research findings into everyday practice. A third explicit priority was to expand the involvement of minority and underserved populations in clinical trials and related research activities, addressing long-standing gaps in trial participation and ensuring results are more applicable to the full diversity of patients affected by cancer.
The CCOP Network was structured around two complementary components. First, CCOP Groups (often simply called "CCOPs") consisted primarily of community-based oncologists and their affiliated practice sites. Their main responsibility was to enroll patients and participants onto NCI-approved clinical trials and to carry out the trial protocols in real-world community care environments. Second, CCOP Research Bases were the entities responsible for designing and conducting the clinical trials themselves, as well as managing the associated data systems, performing analyses, and reporting results. Importantly, the FOA specified that CCOP Research Bases had to be located within either an NCI-supported Clinical Cooperative Group or an NCI-designated Cancer Center, tying community accrual and delivery capacity to robust academic or cooperative group research infrastructure.
The funding mechanism for this opportunity was the NIH U10 cooperative agreement. A U10 is not a traditional grant in which the awardee operates with minimal federal involvement; instead, it reflects a cooperative relationship where NIH/NCI typically maintains substantial scientific and programmatic involvement. This structure fit the CCOP model because it requires close coordination, consistent trial conduct across many sites, rigorous oversight of data quality and participant protections, and alignment with NCI-supported national research priorities.
Administratively, the opportunity was categorized as discretionary funding and listed under health and education-related activity areas, with CFDA number 93.399 (Cancer Control). The announcement was posted May 4, 2009, with an application closing date of July 8, 2009, and an archive date of August 8, 2009. The estimated total funding amount was listed as $21.2 million, and the FOA stated there was no cost sharing or matching requirement.
Eligibility was broad and included many types of U.S.-based organizations capable of supporting clinical research operations and community oncology participation. Eligible applicants included public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), and for-profit organizations other than small businesses. The eligibility list also encompassed Native American tribal governments (federally recognized) and other tribal organizations, along with U.S. territories or possessions. The FOA further clarified additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, eligible federal agencies, faith-based and community-based organizations, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs). This broad eligibility aligned with the CCOP mission of reaching diverse communities and embedding clinical trials in varied care delivery systems.
Overall, this FOA represented a significant NCI effort to integrate cutting-edge cancer clinical trials into community oncology practice, improve the translation of research into routine care, and increase equitable access to clinical trial participation. The program design linked community-based accrual networks with research bases housed in established cooperative groups or NCI-designated cancer centers, aiming to combine local reach with strong centralized scientific leadership, data management, and reporting capacity.
Frequently Asked Questions (FAQs)
What is the Community Clinical Oncology Program (CCOP) (U10) funding opportunity?
The Community Clinical Oncology Program (CCOP) (U10) funding opportunity (RFA-CA-09-022) was a National Cancer Institute (NCI), National Institutes of Health (NIH) initiative to strengthen and expand a nationwide, community-based cancer clinical trials network. It was designed to support high-quality cancer clinical research in the community settings where many patients receive care, rather than limiting trials to major academic medical centers.
Which agency sponsored this opportunity?
This funding opportunity was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
What was the main purpose of the CCOP program?
The program aimed to advance cancer prevention, cancer control, and cancer treatment research by increasing enrollment (accrual) of patients and participants into NCI-approved clinical trials conducted in community settings.
Why did the program emphasize community-based clinical trials?
The CCOP model was built on the idea that state-of-the-art cancer clinical research should be actively carried out in community care settings, since that is where most patients actually receive cancer care. Community oncologists were intended to play a central role in enrolling participants and delivering protocol-based interventions.
What does "accrual" mean in the context of this program?
In this context, "accrual" refers to enrolling patients and participants into NCI-approved clinical trials.
What types of research did CCOP support?
Based on the description, CCOP supported clinical trials and related research activities in cancer prevention, cancer control, and cancer treatment, including work aimed at managing cancer-related symptoms through interventions evaluated in NCI-approved trials.
How was CCOP expected to impact cancer care in the community?
One explicit goal was to improve the overall quality of cancer care in the community by promoting adoption of evidence generated by clinical trials. This was intended to help new standards of care move more quickly from research findings into everyday practice.
Did the program include a focus on minority and underserved populations?
Yes. A stated priority was to expand the involvement of minority and underserved populations in clinical trials and related research activities, addressing gaps in participation and helping ensure trial results are applicable to the diversity of patients affected by cancer.
How was the CCOP Network structured?
The network had two main components: CCOP Groups and CCOP Research Bases. CCOP Groups were primarily community-based oncologists and affiliated practice sites focused on enrolling participants and conducting trial protocols in community settings. CCOP Research Bases were responsible for designing and conducting clinical trials, managing data systems, analyzing data, and reporting results.
What is a CCOP Group (often called a "CCOP")?
A CCOP Group consisted primarily of community-based oncologists and their affiliated practice sites. Their main responsibility was to enroll patients and participants into NCI-approved clinical trials and carry out the trial protocols in real-world community care environments.
What is a CCOP Research Base?
A CCOP Research Base was responsible for the scientific and operational backbone of the trials, including designing and conducting the clinical trials, managing associated data systems, performing analyses, and reporting results.
Were there location or institutional requirements for CCOP Research Bases?
Yes. The funding opportunity specified that CCOP Research Bases had to be located within either an NCI-supported Clinical Cooperative Group or an NCI-designated Cancer Center.
What was the funding mechanism for this opportunity?
The funding mechanism was the NIH U10 cooperative agreement.
How is a U10 cooperative agreement different from a traditional grant?
A U10 is a cooperative agreement, meaning it is not a traditional grant with minimal federal involvement. Under a U10, NIH/NCI typically has substantial scientific and programmatic involvement, which aligns with the need for coordination across many sites, consistent trial conduct, and rigorous oversight of data quality and participant protections.
What was the CFDA number and program area listed for this opportunity?
The opportunity was listed under CFDA 93.399 (Cancer Control) and categorized under health and education-related activity areas.
Was this discretionary or mandatory funding?
It was categorized as discretionary funding.
When was the announcement posted?
The announcement was posted on May 4, 2009.
What was the application closing date?
The application closing date was July 8, 2009.
When was the opportunity archived?
The archive date was August 8, 2009.
How much total funding was estimated for this opportunity?
The estimated total funding amount listed was $21.2 million.
Was cost sharing or matching required?
No. The funding opportunity stated that there was no cost sharing or matching requirement.
Who was eligible to apply?
Eligibility included a broad range of U.S.-based organizations capable of supporting clinical research operations and community oncology participation. Eligible applicants included public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (both 501(c)(3) and non-501(c)(3)), and for-profit organizations other than small businesses. Eligibility also included Native American tribal governments (federally recognized) and other tribal organizations, as well as U.S. territories or possessions.
Were minority-serving institutions and community-based organizations included as eligible applicants?
Yes. The opportunity explicitly included Alaska Native and Native Hawaiian Serving Institutions, faith-based and community-based organizations, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and other eligible federal agencies among the eligible applicant types.
How did the design of this program connect community sites to research leadership?
The program linked community-based enrollment and protocol delivery (through CCOP Groups) with centralized scientific leadership, data management, and reporting capacity (through CCOP Research Bases housed within NCI-supported Clinical Cooperative Groups or NCI-designated Cancer Centers).
What overall outcomes was CCOP trying to accelerate?
By improving accrual at community sites, CCOP sought to speed up development and evaluation of interventions to prevent cancer, treat cancer, and manage cancer-related symptoms, while also helping evidence from clinical trials translate more quickly into routine community practice.
When was the CCOP Network originally established?
The CCOP Network was originally established in 1983.
Browse more opportunities from the same category: Education Health
Next opportunity: Building Capacity to Prevent Sexual Violence through Resources, Training and Technical Assistance
Previous opportunity: NIDCR Small Research Grants for Data Analysis and Statistical Methodology (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 09 022
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 09 022) also looked into and applied for these:
| Funding Opportunity |
|---|
| Technologies and Software to Support Integrative Cancer Biology Research (SBIR) R43/R44 Apply for PA 09 188 Funding Number: PA 09 188 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Technology Development for the Detection and Evaluation of Chemical and Biological Carcinogens (SBIR) R43/R44 Apply for PA 09 187 Funding Number: PA 09 187 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Technology for the Detection and Characterization of Low Abundance Proteins, Peptides, or micro RNAs (SBIR) R43/R44 Apply for PA 09 189 Funding Number: PA 09 189 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Integrating Translational Neuroscience and Adolescent Drug Abuse Treatment (R21) Apply for RFA DA 10 003 Funding Number: RFA DA 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| International Research Collaborations on HIV/AIDS and Drug Use (R01) Apply for RFA DA 10 008 Funding Number: RFA DA 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Centers of Cancer Nanotechnology Excellence (CCNEs)(U54) Apply for RFA CA 09 012 Funding Number: RFA CA 09 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $3,200,000 |
| Cancer Nanotechnology Platform Partnerships (U01) Apply for RFA CA 09 013 Funding Number: RFA CA 09 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $400,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R01) Apply for PA 09 197 Funding Number: PA 09 197 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R21) Apply for PA 09 198 Funding Number: PA 09 198 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Identifying Non coding RNA Targets for Cancer Early Detection and Prevention (R21) Apply for PA 09 200 Funding Number: PA 09 200 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Identifying Non coding RNA Targets for Cancer Early Detection and Prevention (R01) Apply for PA 09 199 Funding Number: PA 09 199 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The National Drug Abuse Treatment Clinical Trials Network (U10) Apply for RFA DA 10 009 Funding Number: RFA DA 10 009 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Bioenergetics, Fatigability, and Activity Limitations in Aging (R21) Apply for PA 09 191 Funding Number: PA 09 191 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Bioenergetics, Fatigability, and Activity Limitations in Aging (R01) Apply for PA 09 190 Funding Number: PA 09 190 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21) Apply for PAR 09 162 Funding Number: PAR 09 162 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Feasibility Studies for Collaborative Interaction for Minority Institution/Cancer Center Partnership (P20) Apply for PAR 09 201 Funding Number: PAR 09 201 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (F31) Apply for PA 09 208 Funding Number: PA 09 208 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cutting Edge Basic Research Awards (CEBRA) (R21) Apply for PAR 09 222 Funding Number: PAR 09 222 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| Cancer Intervention and Surveillance Modeling Network (CISNET) (U01) Apply for RFA CA 09 025 Funding Number: RFA CA 09 025 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Early Detection Research Network Biomarker Developmental Laboratories (U01) Apply for RFA CA 09 017 Funding Number: RFA CA 09 017 Agency: National Institutes of Health Category: Education Health Funding Amount: $400,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 09 022", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.